For the pharmaceutical industry, the past year was challenged with a new administration that was both unpredictable and unconventional, a new FDA commissioner, and high levels of scrutiny surrounding drug prices and opioid use. This eBook offers current insight on:
- Opioid crisis aftermath: how are pharma manufacturers and regulators dealing?
- Pharma Career and Salary Survey results
- Regulatory intelligence: the most impactful regulatory initiatives from the past year